Biotech Startups

BioStack provides a platform for bioinformatics and experimental science that integrates biological insights with computational technology. The platform serves researchers and scientists working in modern biology and life sciences research.

3 investors

Biostate AI is a biotech company that develops AI-driven solutions for the life sciences and medical research sectors. The company operates multiple international subsidiaries and partnerships focused on advancing genomics and health diagnostics.

3 investors

Biotalys develops protein-based biocontrol products for crop protection, giving farmers tools to prevent crop loss and extend post-harvest protection while reducing food waste. The agritech company builds a pipeline of products with novel modes of action targeting crop pests and diseases across the food value chain.

3 investors

Biotic Labs develops bio-based, biodegradable polymers made from feedstocks such as sea algae and agricultural waste as a direct replacement for conventional plastics. The company serves manufacturers seeking plastic alternatives that integrate into existing production lines while supporting circular economy principles.

3 investors

Bioventus develops orthobiologics and pain treatment products for orthopedic care, offering therapies such as the StimRouter neurostimulation device for chronic peripheral nerve pain. Its portfolio serves patients, physicians, and payers in the medical device and healing space.

3 investors

Bioweg develops biodegradable, bio-based ingredients using microbes and green chemistry to replace microplastics, synthetic polymers, and petroleum-based additives in cosmetics, personal care, agriculture, and food applications. The company creates customizable solutions from food industry waste streams for sustainable alternatives to conventional chemical additives.

3 investors

Blackrock Neurotech develops a neurotechnology platform, including brain-computer interface systems, aimed at improving patient lives and treating neurological conditions. It builds implantable neural interface technology for medical and research applications.

3 investors

3 investors

Bloom Science is a clinical-stage biotech company developing live biotherapeutic products that replicate the effects of the ketogenic diet through the gut-brain axis. Its lead program, BL-001, targets obesity and Dravet syndrome, supported by the IrisRx discovery platform that uses gut commensal microbes and synthetic biology to develop therapies for metabolic and neurological disorders.

3 investors

Genetix Biotherapeutics (formerly bluebird bio) develops gene therapies for patients with rare genetic diseases including sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy. The therapies use modified blood stem cells to restore function of affected genes and offer potential cures rather than symptom management.

3 investors

Boltz develops generative AI models for biomolecular design and drug discovery, used by researchers across pharmaceutical, biotech, agricultural, and academic sectors. The company offers frontier foundation models for protein and small-molecule design through an API with enterprise deployment options.

3 investors

Bonum Therapeutics develops antibody-controlled protein therapeutics that remain inactive until bound to their target, using a sensor-domain mechanism to deliver regulated, targeted activity. Its pipeline focuses on antibody-controlled cytokines for cancer treatment, with potential applications in autoimmune disease, metabolic disorders, and pain management.

3 investors

Bota Bio operates a proprietary Biofoundry platform combining computational algorithms with biotechnology to accelerate design-build-test-learn cycles for bio-manufacturing. Through brands like HeliaGenesis (bio-preservatives, nutritional supplements, and clean label products for food and nutrition) and YuccaElements (synthetic biological materials for personal care), it develops natural, sustainable bio-based ingredients.

3 investors

Boundless Bio develops precision oncology medicines targeting ecDNA-amplified cancers, specifically creating a new category of ecDNA-directed therapies for patients with oncogenic alterations.

3 investors

Braveheart develops treatments for hypertrophic cardiomyopathy and related cardiac conditions. The company focuses on improving the standard of care for patients with these disease types.

3 investors

BreezeBio develops a programmable delivery platform called NanoGalaxy for targeted delivery of genetic medicines to specific cells and tissues. The platform addresses the challenge of enabling genetic payloads to reach their target sites in the body to control biological processes.

3 investors

BrightSpec develops molecular rotational resonance (MRR) spectroscopy instruments and software that identify and quantify gas-phase molecules from complex mixtures without front-end separation. Its analytical platforms serve the pharmaceutical, chemical, and consumer goods industries for tasks such as structure validation, residual analysis, and raw material characterization.

3 investors

Briya builds a data exchange infrastructure that connects healthcare organizations and life sciences organizations to share high-quality medical and clinical data securely and compliantly. The platform is aimed at researchers and hospitals to speed access to data for medical research and treatment development.

3 investors

C2i Genomics develops TrueMRD, a cancer monitoring platform that combines whole-genome sequencing with AI algorithms to build personalized tumor signatures for detecting minimal residual disease (MRD). It is aimed at oncology and clinical cancer monitoring applications.

3 investors

Callio Therapeutics develops next-generation dual-payload antibody-drug conjugates (ADCs) with differentiated payload and linker technologies for targeted cancer treatment. The company's lead program is a dual-payload HER2-targeted ADC designed to deliver drug combinations to tumor cells.

3 investors

Camp4 is a biotechnology company focused on genetic research and neurology, leveraging expertise in genomics and neuroscience for therapeutic development.

3 investors

Capacity Bio is a biotechnology company developing mitophagy modulators — small molecules, peptides, and nanoparticles that target mitochondrial biology to identify and clear dysfunctional mitochondria. Its pipeline includes a first-in-class mitophagy agonist intended for therapeutic use in aging- and disease-related conditions.

3 investors

Capsulomics offers Esopredict, a DNA methylation-based risk-stratification test that predicts progression from Barrett's esophagus to high-grade dysplasia or esophageal adenocarcinoma for gastroenterologists and pathologists. The test is used as a secondary option when the company's primary TissueCypher spatialomics test cannot provide results.

3 investors

Caraway Therapeutics was a preclinical biopharmaceutical company developing small-molecule therapies modulating lysosomal function to treat neurodegenerative and rare diseases. Acquired by Merck in 2023.

3 investors